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Abstract
Background: Hepatic dysfunction is a complication associated with parenteral nutrition (PN). Our primary objective
was to study the relationship between doses of intravenous fish oil (FO) emulsion in PN and the variation in the
main liver function tests (LFTs) in hospitalized PN-treated adults. As a secondary objective, we studied the safety of
FO administration.
Methods: We conducted a retrospective study in adult patients receiving FO supplementation in PN. Demographic,
nutritional and safety variables were collected. Variation of LFTs was defined as the difference between values just
before the first administration of FO and values at the end of PN. A multiple linear regression was performed to
study the association between PN-lipids (FO or vegetable) and the variation of each LFT; the following variables
were used to adjust the effect of lipids: sepsis, length of stay in the intensive care unit and lipids dose. Student
t-test was used to study safety variables. Data were analyzed using SPSS 19.0.
Results: Patients (53, median age 68 years (24–90); 62 % men) with the principal diagnosis of digestive neoplasm
(42 %) received PN for a median of 19 (7–75) days. In the multivariate analysis, the amount of FO was related to a
decrease in gamma-glutamyl transferase (GGT) (B = −2.23;CI95 % = −4.41/-0.05), a decrease in alkaline phosphatase (AP)
(B = −1.23;CI95 % = −2.07/-0.37), and a decrease in alanine aminotransferase (ALT) (B = −0.82; CI95 % = −1.19/-0.44). No
differences were found in safety variables.
Conclusions: GGT, AP and ALT improved with FO PN-supplementation. Moreover, the improvement was greater when
the doses of FO were higher. FO administration in PN is safe.
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Background
Fat is increasingly recognized as a central feature of
many biological processes [1]. Lipid emulsions are an es-
sential part of parenteral nutrition (PN), both as an en-
ergy supply and as a source of essential fatty acids (FAs)
[2]. Furthermore, they are involved in the structure and
function of cell membranes and receptors, modifying
gene expression and modulating the inflammatory and
immune responses [2]. Moreover, FAs are precursors of
prostaglandins and other eicosanoids and have therefore
important metabolic functions [2].
The development of significant hepatic dysfunction is a
well-recognized complication associated with PN adminis-
tration [2, 3]. A spectrum of hepatobiliary disorders, ran-
ging from simple steatosis to cholestasis, cholelithiasis,
hepatic fibrosis and subsequent progression to cirrhosis,
portal hypertension and end-stage liver disease, can occur
[4]. This disorder is characterized by elevated serum levels
of total bilirubin (BIL), alkaline phosphatase (AP), gamma-
glutamyl transferase (GGT) and transaminases (alanine
aminotransferase [ALT] and/or aspartate aminotransferase
[AST]) [2, 3, 5]. Cholestasis and hepatocellular damage are
well-known complications caused by long-term PN,
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especially in the neonatal and pediatric population but also
in adult patients with short bowel syndrome (SBS). In adult
patients, this hepatic dysfunction may be present as chole-
stasis, hepatosteatosis or cholelithiasis [5]. Parenteral
nutrition-associated liver disease (PNALD) is well estab-
lished in patients with long-term home PN treatment. But
it is also true that those patients who only receive PN dur-
ing hospitalization have the potential to develop alterations
in their LFTs [6, 7]. Although liver failure develops slowly
over months or years, steatosis and steatohepatitis may de-
velop within weeks in acutely ill patients [4]. This liver al-
teration is normally transient, and may not progress to a
worse condition. However, it could add to those liver alter-
ations caused by drugs and specific clinical situations and
might also pose a limitation to a correct intravenous nutri-
ent supply.
The mechanisms leading to PNALD remain largely un-
known but are likely to be multifactorial [2, 5, 8]. Estab-
lished risk factors for its development are duration of PN
and number of septic episodes [9], but several aspects of
the parenteral formula have also been thought to be
responsible for these liver test abnormalities [10, 11].
Macronutrient excess, i.e., feeding beyond the liver’s ability
to use carbohydrate and fat, can cause accumulation of
by-products in the liver and result in hepatic injury. An-
other cause is the source of fat used. Lipids coming from
soybean oil (SO) have high levels of ω-6 and are associated
with liver toxicity, mainly with long-term utilization. After
them, median chain triglycerides (MCT) were combined
with SO in order to provide energy quickly and avoid
some of the secondary effects detected with SO. Olive oil-
based lipids were introduced later with potentially fewer
lipoperoxidation problems; and recently, lipids derived
from fish have been reported to have anti-inflammatory
activity. Combinations of all these lipids have appeared on
the market and their use has been extended. The long-
term use of these emulsions has permitted their correl-
ation with different types of PNALD and with recovery
from PNALD in premature and home parenteral nutrition
patients. Initially, in our hospital, only SO was used but, as
soon as different products for inflammatory conditions
were marketed, we also introduced them in our clinical
protocol. These decisions were based on clinical experi-
ence, coming mainly from the clinical guidelines of the
European Society of Parenteral and Enteral Nutrition
(ESPEN). In addition, vegetable oil-based lipid emulsions
contain significant quantities of phytosterols that accumu-
late in patients’ serum and result in cholelithiasis [10].
Long-term use of soybean oil (SO)-based emulsions leads
to a progressive increase of phytosterol content in cell
membranes and plasma lipoproteins which has been asso-
ciated with the onset of PNALD in children receiving
long-term PN [9]. SO also depletes vitamin E from plasma
lipoproteins and may contribute to hepatic injury [12].
Inflammation is another crucial factor and ω-6 long chain
polyunsaturated fatty acids (PUFAs) have been shown to
worsen inflammatory states and to have immunosuppres-
sive effects [9]. The peroxidative nature of ω-6 could in-
crease inflammatory activity in an infectious (sepsis) or
non-infectious episode [4].
Some evidence has suggested that the administration of
FO-based lipid emulsions may be useful in reversing
PNALD [13]. These emulsions are primarily composed of
ω-3 PUFAs. In Europe, FO can be used both as part of a
standard lipid emulsion or as a supplement, alone or in
combination with other lipid emulsions. FO is mostly used
to attenuate the patient’s inflammatory state and not to
modify liver function. The purpose of this study was to
test, in routine clinical practice, whether there is an influ-
ence of FO on LFTs in adult patients treated with PN dur-
ing hospitalization.
Our main objective was therefore to study the rela-
tionship between the doses of intravenous FO emulsion
supplementation and the variation in the main LFTs in
adult patients receiving PN during hospitalization. As a
secondary objective, we studied the safety of the doses of
FO given.
Methods
This was a retrospective study conducted over a 16-
month period in a 600-bed, third-level teaching hospital.
Patients included in the study met the following criteria:
older than 17 years of age, receiving FO supplementa-
tion in PN and not receiving enteral nutrition or oral
food. Those patients with liver disease previous to PN
initiation were excluded.
Data were collected in several categories: demographic
variables (gender, age, height and weight); clinical vari-
ables (diagnosis, indication for PN administration, sepsis
episodes, length of stay [LOS] in intensive care unit
[ICU] and death); and nutritional variables (length of
treatment with PN and amount of parenteral macronu-
trients administered). Nutritional data were collected
from the database program of PN in the Pharmacy De-
partment. Analytical and clinical data were collected
from the hospital’s computerized database.
Lipids were given as: Clinoleic® (Baxter, Lessines,
Belgium) based on a mixture of purified olive oil (80 %)
and SO (20 %); SMOFlipid® (Fresenius Kabi, Bad Homburg,
Germany) based on SO (30 %), MCT (30 %), olive oil
(25 %) and FO (15 %); and Omegaven® (Fresenius Kabi,
Bad Homburg, Germany), an emulsion exclusively of
FO. In our study the amount of lipids administered by
source, either vegetable (SO, MCT, olive oil) or not (FO),
was studied separately.
In our routine practice, according to our protocol,
lipids in PN are administered as a maximum dose of
1 g/kg/day, although this dose is reduced in situations of
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hypertriglyceridemia. Primarily, when the patient pre-
sents an inflammatory state, SMOFlipid® is used. How-
ever, in those patients with a high inflammatory state a
combination of Omegaven® and Clinoleic® is used in
order to achieve higher proportions of FO (with a max-
imum of 50 % of the dose). To classify the inflammatory
state, we used C-reactive protein (CRP) [mg/L] and pre-
albumin [mg/L] as biochemical and immunology param-
eters, since they are acute phase proteins. Nevertheless,
in the extreme situation, even when the prealbumin is
not so low, we maintained high proportions of omega-3
if CRP values were high. A third parameter that we have
taken into account is plasma triglycerides [mmol/L] be-
cause of the better clearance of omega-3 lipids [4]. In
addition to these parameters we have also taken into ac-
count the clinical situation of the patient. In cases of
hypertriglyceridemia where the total dose is reduced,
lipids are given only as Omegaven®. Once FO emulsion
was introduced in the nutritional formula, it was contin-
ued until the end of PN treatment. So, the same patient
could receive different types of lipids according to their
clinical situation All patients studied received a fixed
standard daily supplementation of trace elements and
vitamins.
Assessment
Venous blood samples were taken at the beginning of
treatment with PN containing FO and twice a week
thereafter. Liver function assessment was carried out
with measurements of GGT, AP, ALT and BIL. On the
other hand, safety variables were only determined at the
beginning of the study and at the end of PN treatment;
these variables were serum triglyceride (TG) levels and
markers of coagulopathy: platelets count (PLC) and the
international normalized ratio (INR).
Statistical analysis
For the statistical analysis, the principal variable chosen
was the variation of LFTs. It was defined as the differ-
ence between LFT values just before the first administra-
tion of FO in the PN and the final values at the end of
PN administration (results of these differences could be
positive or negative according to an elevation or a dim-
inution in the parameter, respectively).
Using this principal variable, two different statistical
models were constructed:
1) Univariate model
The association between the variation in the liver
parameters and the total dose of FO administered
during the study (g/kg) was evaluated by one-way
analysis of variance (ANOVA). Five categories were
defined according to the variation found in each
liver parameter: the values of the variations obtained
were classified as high increase (including patients
above with an increase superior to the 80th percentile),
moderate increase (from the 60th to the 80th
percentile), no modification (between the 40th and
60th percentile), moderate decrease (20th and 40th
percentile) and high decrease (with a variation of
less than the 20th percentile).
2) Multivariate model
A multiple linear regression model was constructed
to study the relationship between each LFT variation
as a continuous variable and the amount of FO
given adjusted in accordance with four important
variables of liver co-morbidity:
– Presence of sepsis when each liver parameter
presented the highest value. According to the
American College of Chest Physician/Society of
Critical Care Medicine (ACCP/SCCM) consensus
conference, sepsis was established when the
patient presented at least two of the following
criteria: (a) body temperature ≥38 °C or ≤36 °C,
(b) tachycardia with heart rate ≥90 beats/min, (c)
tachypnea with paCO2 ≤ 32 mmHg or mechanical
ventilation; (d) leukocytes >12x109cells/L [14].
– LOS in ICU considered as the number of days
that the patient stayed in ICU.
– Dose of lipids. This variable contained two
different elements: FO and vegetable-based lipids.
In order to avoid the co-linearity effect between
them, the amount of FO was introduced in the
statistical model adjusted by residuals.
Additionally, in order to check the safety of FO admin-
istration, differences between the beginning and the end
values for safety variables (TG, PLC and INR) were stud-
ied with t-test for paired samples.
All data were analyzed using SPSS 19.0 (SPSS INC,
Chicago IL, USA). Statistical significance was reported with
a 95 % confidence interval at the conventional p < 0.05
level (two-tailed).
Written informed consent was considered not neces-
sary for the study, as it was a non-interventional study.
Parenteral nutrition and nutritional and safety vari-
ables were prescribed and collected according to clinical
practice. Patient data were anonymized for the purposes
of this analysis. Confidential patient information was
protected according to national normatives. This manu-
script has been revised for publication by the Clinical
Research Ethics Committee of our Hospital.
Results
During the total study period (January 2010 to April
2011), 53 patients received PN-FO supplementation and
were included in the study. Median age was 68 (24–90)
years, median weight was 70 kg (40–158) and 62 % of
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participants were men. Patients received the standard
drug treatment for their pathology.
The most frequent diagnosis was digestive neoplasm
(42 %) (Table 1) and the main indication for PN admin-
istration was paralytic ileus or intestinal failure. Overall,
40 patients stayed in ICU with a median LOS of 9.5 days
(2–99). Among the studied patients, 8 died during the
follow-up period (15.1 %).
The median length of treatment with PN was 19
(7–75) days. In Table 2, the amount of nutrients is
described. Altogether, types of lipids administered to
the patients were: 24 % SO, 18.8 % MCT, 36.6 %
olive oil, 20.6 % FO. The most frequent emulsion
used to supply lipids was a combination of Clinoleic®
with Omegaven®.
Among the 23 septic patients, 22 (95.6 %) presented
their highest values of GGT, AP or ALT during the sep-
tic event; while 23 (100 %) had their highest value of BIL
simultaneously with the sepsis.
Statistical results
In the univariate model ANOVA, variation of LFTs was
categorized and the number of patients classified in each
group is shown in Table 3. ANOVA results showed that
there were statistically significant differences regarding
AP. Those patients with a higher decrease of AP had re-
ceived higher doses of FO. The mean of the total dose re-
ceived was 8.96 g/kg in those with a high decrease of AP.
No significance was found between the total dose of
FO and GGT; a trend towards significance was found in
ALT and BIL (Table 3).
In the multivariate model, variation of LFTs was consid-
ered as a continuous variable and the following statistically
significant results were obtained (Table 4 and Fig. 1):
– The variable associated with an increase in GGT
values was sepsis, B = 5.03 [CI 95 % = 0.29/9.76],
however, the total amount of FO administered was
associated with a decrease in GGT, B = −2.23 [CI
95 % = −4.41/-0.05].
– The increase of AP was associated with sepsis, B = 2.25
[CI 95 % = 0.43/4.07] and a greater number of days in
ICU, B = 0.08 [CI 95 % = 0.03/0.14]. On the other
hand, the total amount of FO administered was
associated with a decrease in AP, B = −1.23 [CI
95 % = −2.07/-0.37].
– ALT values only showed association with one variable:
ALT decreased when the dose of FO administered
increased B = −0.82 [CI 95 % = −1.19/-0.44].
– Finally, increases in BIL were only associated with a
longer stay in ICU B = 1.97 [CI 95 % = 1.11/2.84].
Determination coefficients (R2) were consistent.
In the t-tests for safety variables, no differences were
found in the serum TG levels: initial TG median value
1.7 mmol/L (1.1-3.6) and final TG median 1.7 mmol/L
(1.0-3.4) (p = 0.666). With regards to coagulation
markers, no differences, but a trend to significance, was
found in PLC and INR values between the beginning
and the end of treatment. PLC initial median 315×109
cells/L (54×109-1285×109) vs. final median 368×109 cells/L
(30×109-834×109) (p = 0.073); and INR initial median 1.22
(0.94-2.56) vs. final median 1.2 (0.78-1.194) (p = 0.059).
Discussion
This study demonstrated that, when administering FO
supplementation to adult patients treated with PN dur-
ing hospitalization, higher doses of FO were associated
with an improvement in some liver parameters (GGT,
AP and ALT), regardless of other factors that are nor-
mally associated with the alteration of these LFTs in pa-
tients undergoing PN treatment.
To our best knowledge, little research has been con-
ducted on the management of liver alteration in adults
during hospitalized PN treatment with FO. In fact, very
few studies have focused on adults with SBS and
PNALD [13, 15], while other aspects of the potential
benefits of Omegaven® in reducing infections and im-
proving postoperative health outcomes in the critically
ill population have been well studied [16].
LFT alterations associated with PN is a frequent finding
and can be related to many factors [17], among them
intravenous lipid administration [18] since in 1982, Allar-
dyce [19] reported on the prevention of cholestasis with
the use of lipid reduction strategies. The cause appears to
be at least partially associated with the composition of the
SO lipid emulsions that aggravates or induces hepatocellu-
lar and systemic inflammatory effects [4]. Lipid metabol-
ism results in lipid peroxidation and free radical
formation, causing functional damage to hepatocytes,
leading to reduced bile production and cholestasis in ani-
mal models. The higher oxidation susceptibility of ω-6
Table 1 Diagnosis
Diagnostic n (%)
Digestive neoplasm 22 (42 %)
Pancreatitis 7 (13 %)
Other digestive diseases 6 (11 %)
Septic shock 5 (9 %)
Multiple trauma 4 (8 %)
Cardiovascular disease 3 (6 %)
Other neoplasm 3 (6 %)
Status epilepticus 2 (4 %)
Respiratory disease 1 (2 %)
Total 53 (100 %)
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PUFAs requires antioxidant enrichment to counteract for-
mation of reactive oxygen species, although currently uti-
lized levels may not be sufficient [9]. Following these
concerns, several alternatives were investigated and, al-
though the precise mechanism by which these effects are
triggered has yet to be clearly determined, parenteral FO
administration shows several advantages that could ex-
plain the improvement in liver function. FO lipid emul-
sion lacks hepatotoxic phytosterols [20, 21]; improves
biliary flow and cholestasis; and it has been shown to be
effective in lowering triglyceride levels by increasing their
clearance [4, 22]. Owing to their high concentration of ω-
3 PUFAs [20], FO has an anti-inflammatory potential via
competitive inhibition of the ω-6 PUFAs-derived pro-
inflammatory eicosanoids [23] linked to liver injury caus-
ing both apoptosis and necrosis in many types of liver
disease (cholestasis, non-alcoholic fatty liver disease, alco-
holic cirrhosis and hepatitis) [5]. That is why some authors
propose, in line with our results, that increasing the hep-
atic content of ω-3 PUFAs could decrease inflammatory
activity in acute hepatitis with alleviation of hepatic injury
and inflammation [23]. Parenteral FO is enriched with
high levels of the antioxidant α-tocopherol to counteract
possible oxidative risk [9], while other lipids contain γ-
tocopherol and have less anti-oxidative effects [24].
Table 2 Main nutritional and analytical variables collected
during the study
Variables Median (range)
Body Mass Index (BMI) 25.4 (17.3–41.5)
Parenteral Nutrition regimen
Total non-protein calorie (kcal/kg/d) 16.7 (7.7–28.3)
Proteins (g/kg/day) 1.04 (0.43–1.88)
Total fat (g/kg/day) 0.61 (0.22–1)
Fish oil emulsion (g/kg/day) 0.07 (0.01–0.9)
Dextrose (g/kg/day) 2.73 (1.17–4.58)
Laboratory Initial PN Final PN
Serum albumin (g/L) 28 [15–42] 30 [15–38]
Serum prealbumin (mg/L) 123 (17.6–209) 199 (41.1–290)
C-Reactive protein (mg/L) 186.4 (3.6–405.6) 133.7 (2.4–339.5)
Bilirubin (μmol/L) 8.25 (2–151) 7.0 (2–358)
Alanine aminotransferase (μkat/L) 0.32 (0.11–4.67) 0.55 (0.11–5.83)
Alkaline phosphatase (μkat/L) 1.4 (0.5–11) 3.0 (0.6–14.20)
Gamma-glutamyl transferase
(μkat/L)
1.29 (0.17–8.51) 4.28 (0.16–46.72)
Triglycerides (mmol/L) 1.7 (1.1–3.6) 1.7 (1.0–3.4)
Platelet count (x109cells/L) 315 (54–1285) 368 (30–834)
International normalized ratio (INR) 1.22 (0.94–2.56) 1.20 (0.78–1.94)
Table 3 Analyses of variance between doses of fish oil and the variation of each liver parameter
Gamma-glutamyl transferase variation
Variation category High increase Moderate increase No modification Moderate decrease High decrease p
n 10 8 9 19 7 0.156
FO dose meana 1.69 0.64 1.08 3.61 4.47
Rank 0.01–6.44 0.02–2.79 0.04–2.25 0.17–22.56 0.4–13.12
Alkaline phosphatase variation
Variation category High increase Moderate increase No modification Moderate decrease High decrease p
n 8 16 16 7 6 0.000
FO dose meana 2.22 1.16 1.72 1.41 8.96
Rank 0.01–6.44 0.02–2.79 0.05–12.6 0.3–3.6 3.36–22.56
Alanine aminotransferase variation
Variation category High increase Moderate increase No modification Moderate decrease High decrease p
n 7 10 23 7 6 0.094
FO dose meana 0.66 0.57 2.73 3.77 5.32
Rank 0.01–1.52 0.02–2.47 0.04–13.12 0.24–12.6 0.3–22.56
Bilirubin variation
Variation category High increase Moderate increase No modification Moderate decrease High decrease p
n 5 11 15 14 8 0.057
FO dose meana 1.94 0.71 1.35 3.69 5.28
Rank 0.3–6.44 0.02–1.63 0.02–3.6 0.22–13.12 0.03–22.56
FO fish oil
SD Standard deviation
aMean of the total dose of fish oil emulsion administered, expressed in g/kg
Figures marked in bold are statistically significant in the study
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Finally, FO-containing emulsions improve splanchnic
blood flow [2, 25, 26].
Clinically, the relationship between ω-3 FAs and liver
function has been more intensively studied in children
with SBS and PNALD. Since Gura et al. [27, 28] pub-
lished their first papers on the subject, many publica-
tions have appeared showing different strategies to deal
with this problem [29–32]. Currently, even if there is
some concern that the improvement found in PNALD
in children might be due to lipid dose reduction rather
than the type of lipid administered [33] a systematic re-
view by Seida et al. [34] concluded that the best available
evidence at present supports the use of ω-3 FAs supple-
mentation to improve biochemical outcomes of PNALD
in young children dependent on PN.
There are some studies on FO administration in adult
patients with SBS and PNALD. Xu et al. [13] in a 15-
patient study, found that bilirubin normalized after
4 weeks of treatment when SO content of PN was par-
tially replaced by FO up to 10 g daily, about 0.15-0.2 g/
kg/d. Differences in ALT values were also statistically
significant. Nevertheless, even when GGT values also de-
creased, statistically significant differences were not
found. Venecourt et al. [35] showed that after changing
one patient to a total FO emulsion, bilirubin decreased
over the ensuing 8 weeks, with normalization of transami-
nases in 10 weeks. In the case of Burns et al. [36], FO ad-
ministration decreased total bilirubin; AP initially
increased but subsequently declined to a stable pretreat-
ment value and transaminases slightly decreased initially
and then remained stable. In a patient described by
Jurewitsch et al. [37] the change to a blend of FO plus SO
curtailed the increase in liver enzymes but did not reduce
total bilirubin levels. It was subsequently decided to give
only FO and total bilirubin levels fell rapidly. The main dif-
ference between those patients and ours is that all those
patients had established liver disease when they started
treatment with FO and they had developed liver disease
after a long period of PN treatment: 110 days in the Jure-
witsch study [37], 3 years in the Venecourt paper [35] and
5 years in Burns [36]. In the Xu study [13], patients devel-
oped PNALD after 2–19 months of treatment with PN. In
our patients, we found a significant decrease in AP, GGT
and ALT values, even when they had received PN for a
short period of time (median of 19 days) and they did not
achieve this status of an advanced form of liver disease. On
the other hand, the main commercial emulsions that we
used to provide lipids were the combination of Clinoleic®
with Omegaven® and no studies yet show whether the
immunoneutral effect of high amounts of olive oil could
contribute to the improvement of some liver parameters.
Studies on LFT alterations and hospitalization-PN ad-
ministration using FO in adults are scarce. Our results on
ALT improvement with FO agree with those found in the
bibliography. In patients undergoing liver transplantation,
Zhu et al. [38] found that ALT improved significantly after
9 days of FO supplementation (0.2 g/kg/d) compared with
traditional PN support (LCT:MCT). Total lipid intake was
1 g/kg/d. In a randomized, double-blind trial comparing
SMOFlipid® with olive oil in patients following major ab-
dominal surgery or large cranio-maxillo-facial resections
for cancer, Piper et al. [2] found that significantly lower
ALT values were observed at days 2 and 5 in the SMOFli-
pid® group. Pawlik et al. [39] randomized a group of low-
weight newborn infants to receive an intravenous mixture
of Clinoleic® plus Omegaven® or just a Clinoleic® paren-
teral emulsion. They found that, after 22 days of PN
administration, 3 infants in the FO group developed cho-
lestasis compared with 20 infants in the standard group
(RR 0.18; 95 % CI, 0.055–0.56). The results of these publi-
cations agree with our results in the sense that they treat
patients without PNALD, during a similar period of time
and they have similar improvement in the LFTs. Our study
goes beyond the previous ones by finding that increasing
the dose of FO increases the improvement of ALT values
independently of other factors.
Hepatic lipid accumulation is the result of an imbalance
in de novo lipogenesis, FA oxidation, and/or TG secretion
rates [40] and these mechanisms may also be involved in
hepatic steatosis (with ALT and GGT elevation) occurring
Table 4 Multiple lineal regressions between liver parameters variation and four factors that can affect them
Liver parameter
Variable Gamma-glutamyl transferase Alkaline phosphatase Alanine aminotransferase Bilirubin
B CI 95 % p B CI 95 % p B CI 95 % p B CI 95 % p
Sepsis 5.03 [0.29/9.76] 0.038 2.25 [0.43/4.07] 0.017 0.36 [−0.46/1.18] 0.38 −11.04 [−39.2/17.1] 0.43
Total vegetable lipids dose −0.077 [−0.31/0.152] 0.50 −0.03 [−1.11/0.06] 0.175 −0.11 [−0.05/0.03] 0.56 −0.47 [−1.82/0.88] 0.49
Total fish oil dose −2.23 [−4.41/-0.05] 0.045 −1.23 [−2.07/-0.37] 0.005 −0.82 [−1.19/ -0.44] 0.000 −1.81 [−14.8/11.1] 0.78
Length of stay in the intensive
care unit
0.05 [−0.10/0.20] 0.50 0.08 [0.03/0.14] 0.005 −0.01 [−0.04/0.01] 0.31 1.97 [1.11/ 2.84] 0.000
Determination Coefficient R2: 0.15 R2: 0.33 R2: 0.31 R2: 0.34
CI confidence interval
Figures marked in bold are statistically significant in the study
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as a consequence of PN [17]. Increased intake of ω-3
PUFAs has been found to protect against fatty liver disease
since it reduces hepatic lipogenesis and decreases the level
of inflammation. Benefits have been noticed in patients
with non-alcoholic fatty liver disease [41] and in animal
studies on PNALD [21, 22, 40].
Among chronic liver diseases, the association between
adipokines and non alcoholic fatty liver disease is well
established. Adiponectine, the most abundant adipose-
specific adipokine, decreases hepatic and systematic in-
sulin resistance, and attenuates liver inflammation and
fibrosis. That is why recent therapeutic strategies have
focused on the indirect upregulation of adiponectin. In
addition to its relation with chronic liver alteration, early
data suggest that plasma levels of adiponectin are de-
creased in critical illness. Nevertheless, the detailed
Fig. 1 Representation of the B 95 % confidence interval of the four risk factors associated to each liver function test
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mechanisms underlying its hepato-protective functions
remain largely uncharacterized [42–44].
No safety problems were detected in our patients since
no significant differences were found when comparing
serum levels of TG and coagulation parameters. The
product labeling for the FO-based ILE indicates that it
could increase bleeding risk, nevertheless authors such as
Bays [45] and Harris [46] concluded that ω-3 PUFAs do
not increase this risk. Results from Puder et al. [47] are in
line with ours suggesting that FO has a limited effect on
coagulation since the infants receiving FO had lower INR
values and increased platelet counts compared with those
treated with SO, moreover they point out that this incre-
ment in platelet counts suggests a possible improvement
in liver function. The same authors [44] reported that the
rate of hypertriglyceridemia in children receiving FO was
lower than in children receiving SO; and TG levels in the
FO group were lower (P =0.0002) and declined faster than
in the SO group. Differences in levels and trends were sta-
tistically significant (P < 0.0001).
Some limitations can be attributed to this present study,
such as the retrospective collection of data, even when the
high degree of computerization reached in our hospital has
allowed us to find almost every single piece of data that we
wanted to study. Another possible limitation is that we did
not study the amount of α-tocopherol administered. This
could be important, and would be an interesting further
avenue to explore since it is presently unclear whether the
beneficial effects are caused by FO, α-tocopherol or by the
exact mixture of the lipid components. On the other hand,
histopathological measurements could have been under-
taken to prove subclinical damage but, since they are not
standard clinical procedures, they were not performed due
to both ethical and financial concerns.
Conclusions
Although the use of FO lipid emulsion as monotherapy is
still questioned, some groups have shown that children re-
ceiving PN with Omegaven® monotherapy improve their
LFTs and do not develop any signs of essential fatty acid
deficiency or growth retardation [22]. Studying the effect
of FO in adults, we have seen a clear improvement in
some liver parameters (ALT and GGT) in a group of adult
patients treated with PN during hospitalization. In
addition, this improvement is larger when the dose of FO
is increased. Since FO has been tried as a single lipid ad-
ministered as PN in children and taking our results into
account, it would be of interest to use higher doses of FO
in those adult patients who develop liver parameter alter-
ations during hospitalization with PN treatment. Random-
ized trials are needed to confirm this proposition.
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